Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Current Assets (2020 - 2023)

Cullinan Therapeutics has reported Current Assets over the past 4 years, most recently at $476.7 million for Q3 2023.

  • Quarterly results put Current Assets at $476.7 million for Q3 2023, down 18.1% from a year ago — trailing twelve months through Sep 2023 was $476.7 million (down 18.1% YoY), and the annual figure for FY2022 was $474.5 million, up 59.99%.
  • Current Assets for Q3 2023 was $476.7 million at Cullinan Therapeutics, down from $498.2 million in the prior quarter.
  • Over the last five years, Current Assets for CGEM hit a ceiling of $622.8 million in Q2 2022 and a floor of $212.3 million in Q4 2020.
  • Median Current Assets over the past 4 years was $423.2 million (2021), compared with a mean of $417.1 million.
  • Peak annual rise in Current Assets hit 80.81% in 2022, while the deepest fall reached 27.94% in 2022.
  • Cullinan Therapeutics' Current Assets stood at $212.3 million in 2020, then skyrocketed by 39.71% to $296.6 million in 2021, then surged by 59.99% to $474.5 million in 2022, then increased by 0.47% to $476.7 million in 2023.
  • The last three reported values for Current Assets were $476.7 million (Q3 2023), $498.2 million (Q2 2023), and $399.0 million (Q1 2023) per Business Quant data.